Shenglan Huang

478 total citations
23 papers, 295 citations indexed

About

Shenglan Huang is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shenglan Huang has authored 23 papers receiving a total of 295 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Cancer Research and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shenglan Huang's work include Ferroptosis and cancer prognosis (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Shenglan Huang is often cited by papers focused on Ferroptosis and cancer prognosis (9 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (5 papers). Shenglan Huang collaborates with scholars based in China. Shenglan Huang's co-authors include Jianbing Wu, Lingling Zhuang, Dan Li, Li‐Ying Sun, Mao Ye, Zhifeng Zhou, Shuping Chen, Yunbin Ye, Mingshui Chen and Wansong Lin and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Frontiers in Immunology.

In The Last Decade

Shenglan Huang

20 papers receiving 291 citations

Peers

Shenglan Huang
Bao‐Ye Sun China
Mara Persano Italy
Chuanchao He China
Vanessa Rüsseler Germany
Liye Tao China
Thi Bich Uyen Le Singapore
Xueying Hou China
Jingquan Jia United States
Andrew Harrington United States
Motohiro Kojima Japan
Bao‐Ye Sun China
Shenglan Huang
Citations per year, relative to Shenglan Huang Shenglan Huang (= 1×) peers Bao‐Ye Sun

Countries citing papers authored by Shenglan Huang

Since Specialization
Citations

This map shows the geographic impact of Shenglan Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shenglan Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shenglan Huang more than expected).

Fields of papers citing papers by Shenglan Huang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shenglan Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shenglan Huang. The network helps show where Shenglan Huang may publish in the future.

Co-authorship network of co-authors of Shenglan Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Shenglan Huang. A scholar is included among the top collaborators of Shenglan Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shenglan Huang. Shenglan Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Zeng, Jiayu, Kan Liu, Dan Li, et al.. (2024). USP11 promotes lipogenesis and tumorigenesis by regulating SREBF1 stability in hepatocellular carcinoma. Cell Communication and Signaling. 22(1). 550–550. 2 indexed citations
4.
Zhang, Qian, Yi Li, Qingshan Deng, et al.. (2024). Research progress on the role of PTEN deletion or mutation in the immune microenvironment of glioblastoma. Frontiers in Oncology. 14. 1409519–1409519. 3 indexed citations
5.
Li, Dan, et al.. (2023). CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma. Current Oncology. 30(3). 2653–2672. 3 indexed citations
6.
7.
Huang, Shenglan, et al.. (2022). DLGAP4 acts as an effective prognostic predictor for hepatocellular carcinoma and is closely related to tumour progression. Scientific Reports. 12(1). 19775–19775. 7 indexed citations
8.
9.
Huang, Shenglan, et al.. (2022). ARPC2: A Pan-Cancer Prognostic and Immunological Biomarker That Promotes Hepatocellular Carcinoma Cell Proliferation and Invasion. Frontiers in Cell and Developmental Biology. 10. 896080–896080. 6 indexed citations
10.
11.
Sun, Li‐Ying, Jian Zhang, Kai Wen, et al.. (2022). The Prognostic Value of Lysine Acetylation Regulators in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences. 9. 840412–840412. 4 indexed citations
12.
Huang, Shenglan, Li‐Ying Sun, Ping Hou, Kan Liu, & Jianbing Wu. (2022). A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma. Frontiers in Immunology. 13. 944898–944898. 8 indexed citations
13.
Huang, Shenglan, et al.. (2022). A comprehensive prognostic and immunological analysis of ephrin family genes in hepatocellular carcinoma. Frontiers in Molecular Biosciences. 9. 943384–943384. 10 indexed citations
14.
Huang, Shenglan, Dan Li, Lingling Zhuang, Li‐Ying Sun, & Jianbing Wu. (2021). Identification of Arp2/3 Complex Subunits as Prognostic Biomarkers for Hepatocellular Carcinoma. Frontiers in Molecular Biosciences. 8. 690151–690151. 36 indexed citations
15.
Sun, Li‐Ying, Shenglan Huang, Dan Li, et al.. (2021). Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer. Frontiers in Oncology. 11. 754881–754881. 30 indexed citations
16.
Huang, Shenglan, et al.. (2021). A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection. World Journal of Surgical Oncology. 19(1). 168–168. 24 indexed citations
17.
Huang, Shenglan, et al.. (2021). Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients. Frontiers in Molecular Biosciences. 8. 781307–781307. 12 indexed citations
18.
Huang, Shenglan, et al.. (2020). Puerarin alleviates the progression of non-small cell lung cancer by regulating the miR-342/CCND1 axis. Neoplasma. 67(6). 1244–1255. 15 indexed citations
19.
Huang, Shenglan, Zhifeng Zhou, Wansong Lin, et al.. (2018). Exosomes derived from rAAV/AFP-transfected dendritic cells elicit specific T cell-mediated immune responses against hepatocellular carcinoma. Cancer Management and Research. Volume 10. 4945–4957. 52 indexed citations
20.
Shen, Yonghua, Yue Wu, Min Chen, et al.. (2011). Effects of pantoprazole as a HIF-1α inhibitor on human gastric adenocarcinoma sgc-7901 cells. Neoplasma. 59(2). 142–149. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bao‐Ye Sun Breakdown of academic impact, for papers by Mara Persano Breakdown of academic impact, for papers by Chuanchao He Breakdown of academic impact, for papers by Vanessa Rüsseler Breakdown of academic impact, for papers by Liye Tao Breakdown of academic impact, for papers by Thi Bich Uyen Le Breakdown of academic impact, for papers by Xueying Hou Breakdown of academic impact, for papers by Jingquan Jia Breakdown of academic impact, for papers by Andrew Harrington Breakdown of academic impact, for papers by Motohiro Kojima
Rankless by CCL
2026